Molecure SA (WSE: MOC) a Poland-based clinical stage biotechnology company, announced on Monday that it has received approval from the president of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products to carry out the first clinical trial of OATD-02 for the treatment of cancer.
The proposed Phase I trial, an open-label, multi-centre, dose escalation study, is to assess safety, tolerability, anti-cancer activity and will establish the maximum tolerated dose of OATD-02. It will be carried out in Poland and will enrol a maximum of 40 patients with selected advanced and/or metastatic solid tumours including colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma. The study is likely to commence before the end of 2022.
The European Union is to co-finance the clinical trial within the framework of the European Funds Smart Growth and European Regional Development Fund.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project